History

OIC founded by George Robinson and Ross Hyett.

Oxford Technology & Innovations EIS Fund (OTIF) launched.

First exit – Oxitec, purchased by Intrexon Corporation in a $160m cash transaction.

25th OTIF investment in Oxford University spinout OrthoSon, which is revolutionising the treatment of back pain.

£25m raised by OTIF.

First direct co-investment in Diffblue‘s Series A alongside Goldman Sachs.

Christopher Hall joins OIC as Partner, bringing a wealth of legal, corporate finance and early-stage investment experience.

OIC leads Caristo Diagnostics’ £2m Seed round.

James Mallinson joins OIC, bringing a wealth of cross sector Oxford spinout investment experience.

50th OIC investment in Oxford University spinout Oxford Advanced Surfaces, which is transforming how the surface of composite materials are prepared and bonded.

OIC invests in Oxford PV‘s £65m Series D alongside Equinor, Legal & General, Meyer Berger and Xinjiang Goldwind.

OIC moves into Keble College’s H B Allen Centre, the hub of Oxford spinout activity.

PhishAR, a company using AI to target phishing attacks, is the 200^th spinout from Oxford University.

OIC invest in Living Optics’s Seed Round

First investment made in Oxford University spinout SpyBiotech, which is transforming how vaccines to prevent deadly diseases are developed.

OIC makes its fourth investment in ONI‘s $75m Series B financing led by US investors ARCH Venture Partners and Casdin Capital, and included Section 32, ARTIS Ventures, Vertical Venture Partners,  Axon Ventures and Oxford Science Enterprises.

OIC invest in Oxford Quantum Circuits Series A £38m round

OIC invests in OrganOx’s £25m growth funding round to expand its US operations following FDA approval of it metra device in 2021. The round was led by Lauxera Capital Partners with support from existing investors.